What Genetox does

Genetox Co., Ltd. (제네톡스 주식회사) is a privately-held Korean biopharmaceutical company founded in June 2018 and headquartered at the Ucheon Industrial Complex in Hoengseong-gun, Gangwon-do, South Korea. The company develops, manufactures, and exports botulinum toxin Type A products under the BOTAONE brand (100Unit and 200Unit freeze-dried powder formulations) for both aesthetic indications (glabellar wrinkles, crow's feet, facial contouring, calf reduction, hyperhidrosis) and therapeutic applications (cerebral palsy, migraine, chronic pain, muscle spasticity). Its core technology rests on a proprietary Clostridium botulinum Type A strain designated GT-288 and an in-house 99% high-purity purification process, complemented by sustained-release protein formulation, lyophilized powder formulation, and micro-needle/cell-permeating delivery technology. Manufacturing is conducted at a KGMP-certified dedicated GMP facility commissioned in July 2021 with stated annual capacity of 6 million vials, making the company one of the few fully vertically-integrated domestic Korean producers of botulinum toxin in a market historically dominated by imported products.

Genetox generates revenue through direct B2B sales of BOTAONE products to Korean dermatology, plastic surgery, dental, and ophthalmology clinics; through distribution agreements with regional partners (notably CuriBio for Korea/Asia, SINOCRO for China, and Sakura General Hospital for Japan); through product exports to the United States, Japan, and China following MFDS export product approvals (100Units October 2022, 200Units July 2025); and potentially through licensing of proprietary botulinum strain and purification technology. Export certification has been validated by the Korea International Trade Association Export Tower awards at the USD 2M threshold (2023) and USD 10M threshold (2024), and the company received the Inno-Biz technology innovation certification (April 2022), the 2025 Baby Unicorn Program designation from the Ministry of SMEs and Startups, and the 2026 IP Narae Patent Program selection from KIPO.

The company is currently running domestic Phase 3 clinical trials (IND approved March 2025) comparing BOTAONE 100Units head-to-head with Allergan Botox in 326 subjects across 4 Korean sites, and has established US, Japan, China, and Korea clinical-research partnerships (Kinetta, CSSi, DreamCI, Meditip, SINOCRO, Bundang CHA Hospital, Seoul National University Dental Research Institute, Sakura General Hospital) to support international regulatory pathways. Management is led by Representative Director/CEO Lee Young-jun (since 2018) and includes internal director Kim Hae-jin (Marketing Director) and external director Hwang Ji-young. As of late 2025 the company was an active operating biopharmaceutical firm in pre-full-commercial scale, with ownership composed of founding management, financial-institution investors (Hana Bank, Korea SMEs and Startups Agency), and venture designation (KOTEC, October 2019).

Name

Genetox

Legal name

제네톡스 주식회사

Website

https://genetox.co.kr

Company type

Private

Founded year

2018

Operating status

Operating

Short description

Genetox is a privately-held Korean biopharmaceutical company that develops, manufactures, and exports proprietary botulinum toxin Type A products under the BOTAONE brand for aesthetic and therapeutic use, selling to Korean dermatology and specialty clinics and through distribution partners in Japan, China, and the United States.

Ownership category

akta.pro rank

Headquarters

HQ city

Gangneung

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Botulinum Toxin Product Sales: Sale of botulinum toxin products (BOTAONE Inj. 100/200 Units) for aesthetic and therapeutic applications to healthcare providers and distributors domestically and internationally
2. Export/Distribution Revenue: Revenue from exporting products to Japan, USA, China and other international markets through distribution partnerships
3. Technology Licensing: Licensing of proprietary botulinum toxin technology and manufacturing processes to partners

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Core offering

Genetox develops, manufactures, and distributes botulinum toxin Type A products (BOTAONE Inj. 100 Units and 200 Units) derived from its proprietary GT-288 bacterial strain. The company operates a vertically integrated GMP-certified facility producing freeze-dried powder formulations for aesthetic applications (glabellar wrinkles, crow's feet, facial contouring) and therapeutic indications (chronic migraine, hyperhidrosis, cerebral palsy, muscle spasticity). Products are sold domestically to healthcare providers and exported internationally through distribution partners.

Product overview

Genetox is a biopharmaceutical company specializing in botulinum toxin product development, manufacturing, and export. The company operates a single-product focus strategy centered on BOTAONE botulinum toxin products available in 100Unit and 200Unit dosage strengths. Both products contain Clostridium Botulinum Toxin Type A as the active ingredient in freeze-dried powder form with 900kDa complex size. The product portfolio targets both domestic Korean market clinical trials (Phase 3) and international export markets. The company also conducts R&D in next-generation botulinum toxin formulations, therapeutic indications expansion, and sustained-release delivery technologies.

Differentiator

Problem solved

Functional benefit

Brands

• BOTAONE: Botulinum toxin type A product line available in 100 and 200 unit formulations for export and domestic clinical use
• 보타원주

Products and services

• BOTAONE Inj. 100Units Botulinum Toxin Type A freeze-dried powder injection (900kDa complex size) indicated for temporary improvement of moderate to severe glabellar wrinkles and lateral canthal lines in adults. Sold to dermatology and plastic surgery clinics for aesthetic applications.
• BOTAONE Inj. 200Units Higher dosage variant of Botulinum Toxin Type A freeze-dried powder formulation for injection (900kDa complex size). Indicated for adult cosmetic applications and approved for export markets in July 2025.

Quantifiable outcome

• Phase 3 clinical trial with 326 subjects at 4 clinical sites comparing BOTAONE 100 Units efficacy and safety vs Botox
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Twelve partnerships are on record, tiered core and major.

• Japan Sakura General Hospital (사쿠라종합병원)coreStrategic or Co-development Partner · 29 July 2025Strategic MOU for clinical R&D cooperation in Japan. Agreement includes priority introduction of Genetox botulinum toxin products, joint development of beauty and anti-aging protocols within the hospital, and establishment of a Korean-style medical aesthetics education center in Nagoya. Sakura General Hospital will accumulate clinical data to support Japanese regulatory approval processes.
• USA CuriBiocoreChannel Partner/ Reseller/ Distributor · 1 April 2024MOU and Korea/Asia distribution contract signed April 2024. CuriBio serves as exclusive distributor for Korean and Asian markets for Genetox botulinum toxin products.
• China SINOCROmajorStrategic or Co-development Partner · 1 February 2024CRO contract signed February 2024 for clinical development in China market. SINOCRO provides clinical research organization services for regulatory approval process in China.
• DreamCImajorImplementation/ SI/ Consulting Partner · 4 December 2023Global clinical CRO partnership for Phase 1 clinical trial execution. DreamCI collaborates with Genetox for conducting clinical trials for botulinum toxin products.
• Meditip (메디팁)majorImplementation/ SI/ Consulting Partner · 4 December 2023Regulatory consulting partnership for IND approval process. Meditip is Korea's largest pharmaceutical regulatory consulting firm providing Pre-IND, IND, NDA, BLA services. Provided successful support for Phase 1 IND approval.
• USA CSSimajorImplementation/ SI/ Consulting Partner · 1 April 2023CRO contract signed April 2023 for GT-100 clinical development. CSSi (Clinical Support Services inc) provides clinical research organization services for US regulatory pathway.
• Seoul National University Dental Research Institute (서울대 치학연구소)coreStrategic or Co-development Partner · 29 June 2022Joint R&D collaboration MOU for 1 year covering technology exchange for joint research, personnel exchange for joint research development, joint clinical trial business promotion, and botulinum toxin indication expansion. Combines SNU's research expertise with Genetox's formulation development capabilities.
• USA Kinetta (키네타)coreStrategic or Co-development Partner · 12 November 2021MOU for joint development of botulinum toxin therapeutics and global market expansion. Partnership aims for new indication development through US FDA collaborative R&D, targeting both aesthetic and therapeutic applications including beauty and treatment areas. Kinetta has CDMO supply agreement with Samsung Biologics worth USD 6 million.
• Bundang Cha Hospital (분당 차병원)coreStrategic or Co-development Partner · 28 May 2021Joint research MOU for clinical trials and therapeutic indication development of botulinum toxin. Collaboration with Cha Medical University's Bundang CHA Hospital under consultation of Dermatology Professor Kim Dong-hyun. Hospital will serve as key clinical trial site.
• Teragenex (테라젠이텍스)majorGTM or Marketing Partner · 26 June 2020MOU for global botulinum toxin market expansion. Partnership includes global market sales and development strategy establishment, and collaborative research for additional indication development. Teragenex brings market expertise in botulinum toxin sector growing at approximately 10% annually.
• Gangwon-do and Hoengseong-guncoreStrategic or Co-development Partner · 10 June 2020Tripartite investment MOU for KRW 120 billion investment in Hoengseong facility. Agreement includes establishment of headquarters, research institute, and production factory in Ucheon Industrial Complex with commitment to create 60+ jobs.
• Curevo Bio (큐베스트 바이오)majorStrategic or Co-development Partner · 1 June 2020Contract for preclinical trials of botulinum toxin signed June 2020. Curevo Bio conducted preclinical studies required for IND application.

Scale indicators9 records

Recent moves10 records

Expansion highlights7 records

Direct peers

• Hugel: Korean botulinum toxin manufacturer (Botulax/Letybo), directly competing in the same aesthetic and therapeutic botulinum toxin category in Korea and global export markets.
• Medytox: Korean botulinum toxin maker (Neuronox/Meditoxin) with overlapping product portfolio, same regulatory pathway, and competing in similar domestic and export geographies.
• Daewoong Pharmaceutical: Korean competitor with botulinum toxin product Nabota, pursuing similar global expansion strategy and competing head-to-head in both aesthetic and therapeutic indications.
• Ipsen: Global biopharmaceutical company marketing Dysport (abobotulinumtoxinA) in aesthetic and therapeutic indications, directly comparable to BOTAONE in product type and indications.
• Merz Pharmaceuticals: Markets Xeomin/Bocouture (incobotulinumtoxinA), a direct botulinum toxin competitor in both aesthetic and therapeutic segments globally.
• Evolus: US-focused aesthetics company behind Jeuveau (prabotulinumtoxinA), a newer botulinum toxin entrant pursuing similar aesthetics-focused strategy as Genetox.

Broad incumbents

• Allergan Aesthetics (AbbVie): Maker of Botox, the global gold-standard botulinum toxin brand that Genetox directly benchmarks against in its Phase 3 trial; dominates market share globally and in Korea.
• Galderma: Global dermatology-focused company (post-Nestle Skin Health) with botulinum toxin offerings and broader aesthetics portfolio; major competitive force in injectable aesthetics.

Emerging players

• Revance Therapeutics: US aesthetics company with Daxxify (daxibotulinumtoxinA), competing in the same long-acting botulinum toxin category with a differentiated peptide-based formulation.

Regional players

• Huons: Korean pharmaceutical company with botulinum toxin (Huons Botulax via subsidiary) and broader aesthetic injectable portfolio, competing in the same domestic Korean market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genetox